CapEx per share of Zoetis, Inc. Class A – BVL:ZTSUS
This article provides financial information specifically the "CapEx per share" for Zoetis, Inc. Class A, traded under the symbol ZTSUS on the Lima Stock Exchange. The content is primarily a data placeholder, indicating the period, value, change, and change percentage for this metric. It also notes that the market is closed and no trades have occurred for this listing.
Return on invested capital % of Zoetis, Inc. Class A – BVL:ZTSUS
This article displays the return on invested capital percentage for Zoetis, Inc. Class A (BVL:ZTSUS) on the TradingView platform. It primarily consists of navigational elements and copyright information, with financial data provided by ICE Data Services and FactSet. The page indicates that the market was closed.
Return on equity % of Zoetis, Inc. Class A – BVL:ZTSUS
This article provides financial information for Zoetis, Inc. Class A (BVL:ZTSUS), specifically focusing on its Return on Equity (%). The content is from TradingView and indicates that the market was closed at the time of viewing. It lists general financial data and acknowledges various data providers.
Dilution adjustment of Zoetis, Inc. Class A – BVL:ZTSUS
The article from TradingView announces a dilution adjustment for Zoetis, Inc. Class A (BVL:ZTSUS). It appears to be a financial listing or update without detailed article content, providing only the title and market information.
Zoetis, Inc. Class A Balance Sheet – BVL:ZTSUS
This article presents the balance sheet for Zoetis, Inc. (ZTSUS) on the Lima Stock Exchange. As of Q1 2026, the company's total assets were PEN 53.05 billion, a 1.91% increase from Q4 2025, while total liabilities rose by 2.17% to PEN 41.73 billion. The report provides a snapshot of the company's financial position and historical data for assets and liabilities.
Asset turnover of Zoetis, Inc. Class A – BVL:ZTSUS
This article provides asset turnover data for Zoetis, Inc. Class A (BVL:ZTSUS) on the TradingView platform. It appears to be a financial data page rather than an analytical article, showing "Period Value Change Change %" for the asset turnover.
Wondering what's happening in today's after-hours session?
This article provides a summary of top gainers and losers in the US markets during the after-hours trading session on Wednesday. It lists companies like Zoetis (ZTS), IBM, and Society Pass (SOPA) as top gainers, and eBay (EBAY), MasTec (MTZ), and Osisko Development (ODV) among the top losers, often citing recent press releases or significant past performance changes. The article helps investors quickly identify stocks with significant post-market price movements.
VITL Investor Alert: Vital Farms, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Filed Inadequate Disclosures: Levi & Korsinsky
Levi & Korsinsky, LLP is examining the adequacy of Vital Farms, Inc.'s risk disclosures after a securities class action lawsuit was filed. The lawsuit alleges that Vital Farms provided inadequate disclosures regarding its ERP system transition, which caused production slowdowns and shipment delays that were not properly communicated to investors. Shareholders who lost money between May 8, 2025, and February 26, 2026, may seek to lead the class action.
Merchants Bancorp (MBIN) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky, LLP has announced a securities fraud investigation into Merchants Bancorp (MBIN). The investigation comes after a 9.3% drop in share value following the Q1 2026 earnings report, which revealed a significant year-over-year decline in brokered deposits that contradicted the company's publicly stated "strong deposit growth." Shareholders who incurred losses are encouraged to contact Levi & Korsinsky to discuss their legal rights.
Zoetis: Reducing Our Fair Value Estimate, but Shares Remain Undervalued
Morningstar has reduced its fair value estimate for Zoetis (ZTS) due to increased competition from rival Elanco, which led to a 4% operational decline in Zoetis' first-quarter companion animal revenue. Despite this, Morningstar believes Zoetis' wide economic moat remains intact and its shares are still undervalued. The company's performance has prompted a review of its standing.
Qualcomm, Datadog among market cap stock movers on Thursday By Investing.com
This article highlights several market cap stock movers on Thursday, indicating that stocks like Qualcomm (QCOM) and Datadog (DDOG) rallied, while others like Arm (ARM) and Insmed (INSM) experienced declines. It categorizes these movers by market capitalization, detailing percentage changes and key news influencing their performance.
Zoetis' Wide Moat Remains Intact, but We've Lowered Our Fair Value Estimate
Morningstar has reaffirmed Zoetis' wide economic moat rating, acknowledging its leadership and innovation in the animal health industry. However, the firm has also lowered its fair value estimate for Zoetis shares, indicating they remain undervalued despite the slight reduction. This adjustment comes after a previous note highlighting heightened competition and a weak quarter for the company.
Why Zoetis (ZTS) Is Down 10.4% After Trimming 2026 Outlook Amid Weaker Pet Demand
Zoetis Inc. (ZTS) shares fell 10.4% after the company revised its full-year 2026 outlook downwards due to softer U.S. companion animal demand and increased competition. Despite insider share purchases, the Q1 2026 results and reduced guidance challenge the previous optimistic investment narrative. The company's future hinges on stabilizing its U.S. companion animal segment and the success of its innovation pipeline amidst rising competitive pressures.
AT&T Stock Dips Again; Monday’s Test Seen as Key
AT&T stock closed down 2.52% at $24.03 on Friday, extending a three-day loss and a 4.5% weekly drop. This comes despite strategic news including a planned joint venture with Verizon and T-Mobile for rural wireless coverage and the FCC's approval of AT&T's $23 billion spectrum purchase. Investors are now focused on whether the stock can hold the $24 level when trading resumes on Monday, and are looking for further clarity from CEO John Stankey regarding cash flow, debt, and spending.
ALNY Financials: Revenue Breakdown, Margins & Competitor Comparison
Alnylam Pharmaceuticals Inc (ALNY) generates significant revenue from its AMVUTTRA product, which accounts for 76.2% of its total sales, alongside other revenue streams like GIVLAARI and OXLUMO. The company demonstrates strong profitability with an 81.91% gross margin, 23.02% operating margin, and 17.65% net margin, further supported by a high Return on Equity of 90.36%. In a competitive landscape, ALNY, with a market capitalization of $38.32B, shows superior gross margins compared to competitors like ZTS and HLN.
Securities Fraud Investigation Into Prestige Consumer Healthcare (PBH) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announced a securities fraud investigation into Prestige Consumer Healthcare (PBH) following a significant drop in its stock price. This investigation comes after the company reported a revenue decrease of 4.5% organically for fiscal year 2026 and revealed production shutdowns and delayed shipments for Clear Eyes sales, leading to an 11.35% share price decline on May 14, 2026. Shareholders who lost money are encouraged to contact the law firm to inquire about potentially pursuing a claim.
NYSE Composite: Is Miller Industries Cash Flow Outpacing Earnings?
This article examines Miller Industries within the NYSE Composite, focusing on whether its cash flow surpasses its earnings. It highlights the company's operations in industrial manufacturing, specifically towing and recovery equipment, and discusses why accounting results might differ from cash movement in this sector due to production cycles, inventory changes, and payment timing. The broader industrial environment's impact on performance, driven by operational timing and working capital cycles, is also noted.
Zoetis (ZTS) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky is investigating Zoetis Inc. (NYSE: ZTS) after the company announced Q1 2026 results that missed Wall Street expectations and cut its full-year guidance. This led to a significant 21.5% drop in stock price on May 7, 2026, erasing substantial shareholder value. The investigation focuses on whether Zoetis made misleading statements regarding its revenue growth outlook, international sales performance, and competitive pressures.
SPDR S&P 500 ETF Trust (SPY) Daily Update, 5/13/2026
The SPDR S&P 500 ETF Trust (SPY) increased by 0.56% on May 13, driven by a strong performance in AI and semiconductor stocks, despite higher-than-expected inflation data. The ETF saw $4 billion in net inflows over five days and has a Strong Buy rating from analysts with an implied upside potential of 15.67%. Its top holdings with upside potential include Carvana and Loews, while Ciena and Intel are among those with the greatest downside potential.
Zydus to acquire US-based Assertio for $166.4 million
Zydus Lifesciences, through its subsidiary Zydus Worldwide DMCC, will acquire US-based Assertio Holdings Inc for $166.4 million, or $23.50 per share in cash. This acquisition aims to strengthen Zydus's specialty and oncology presence in the US, leveraging Assertio's commercial platform, which includes the oncology drug ROLVEDON®. The deal, structured as a tender offer, is expected to close in the financial year 2026-27.
Can-Fite BioPharma stock price target raised to $5 by H.C. Wainwright on pet drug trial
H.C. Wainwright has increased its price target for Can-Fite BioPharma to $5.00 from $2.50, maintaining a Buy rating, based on upcoming clinical data from a Phase 2 study of piclidenoson for pet osteoarthritis. The drug aims for European and U.S. market approval by 2029 in the significant canine osteoarthritis market, which was estimated at $2.8 billion in 2025. This news comes alongside Can-Fite's recent financial results showing increased net loss and R&D expenses in 2025, but also successful Phase 2a results for namodenoson in pancreatic cancer and a new patent for an obesity treatment.
Why Zoetis (ZTS) Cut 2026 Guidance After Weaker Pet Demand And What It Means Now
Zoetis Inc. reported flat net income for Q1 2026 and lowered its full-year 2026 revenue and earnings guidance due to weaker performance in its U.S. companion animal business. This revised outlook, driven by increased pet owner price sensitivity, fewer veterinary visits, and rising competition, has shifted the investment narrative. Investors are now focused on the stabilization of U.S. companion animal trends and how intensified competition in core pet franchises will impact future performance.
Zoetis Down Over 7%, on Track for Lowest Close Since February 2018 -- Data Talk
Zoetis stock is down over 7% today, currently trading at $67.58, putting it on track for its lowest closing price since February 2018. The trading volume is significantly higher than its 10-day average. The stock has been under pressure following a report concerning an animal-drug recall by its competitor, Elanco.
Ies Holdings stock hits all-time high at 690.31 USD
IES Holdings Inc. (IESC) reached an all-time high of $690.31, reflecting a 171% increase over the past year. Despite this, InvestingPro analysis indicates the stock is currently overvalued. The company recently reported strong Q2 fiscal 2026 results driven by non-residential market expansion, leading Freedom Broker to downgrade its rating to "hold" while raising the price target to $700.
Monday.com Releases Q1 2026 Financial Results
Monday.com Ltd. announced strong first-quarter 2026 results, surpassing Wall Street expectations with non-GAAP earnings of $1.15 per share and revenues of $351.3 million, a 24% increase from the previous year. The company's performance was driven by accelerated demand for its workflow management platform, deepening customer relationships, and expansion into enterprise markets, maintaining a net dollar retention rate of +110.0%. This robust growth and profitability have kept investor interest high, with analysts largely bullish on the stock.
Zoetis (ZTS) Q1 Net Margin Stability Challenges Bullish Acceleration Narratives
Zoetis (ZTS) reported Q1 2026 revenue of US$2.3 billion and basic EPS of US$1.42, showing stable but not rapidly accelerating growth year-on-year. While net margins remain strong at around 28%, defying some bullish expansion narratives, the Q1 net income was slightly lower despite higher revenue. The company's P/E ratio is lower than peers and the broader US pharmaceuticals market, which is partially attributed to slower forecasted growth and a high level of debt identified as a minor risk.
Zoetis Inc (CHIX:ZOEd) Dividend
This page provides an overview of Zoetis Inc (CHIX:ZOEd) dividend information, presenting its stock summary including P/E ratio, P/B ratio, market capitalization, and enterprise value. It also highlights that GuruFocus detected 11 positive signs for ZOEd, inviting users to try a free
Zoetis Inc (CHIX:ZOEd) Stock Price, Trades & News
This article provides a detailed stock summary for Zoetis Inc (CHIX:ZOEd), including its current stock price, market capitalization, financial ratios, and key dates such as earnings calls and general meetings. It also highlights the company's business description, financial strength, growth metrics, profitability, and lists various warning signs detected by GuruFocus. The company, formerly Pfizer's animal health unit, sells anti-infectives, vaccines, parasiticides, and diagnostics for both production and companion animals.
Zoetis Inc (CHIX:ZOEd) Stock Price, Trades & News
This page provides comprehensive financial data, news, and analysis for Zoetis Inc (CHIX:ZOEd), a company specializing in animal health products. It details the stock's performance metrics, financial strength, growth rates, profitability, and valuation, alongside business descriptions, executive information, and upcoming investor events. The article notes a medium warning sign detected by GuruFocus for ZOEd.
Zoetis Resets Outlook As U.S. Pet Weakness Pressures Valuation And Growth
Zoetis (NYSE: ZTS) has lowered its full-year guidance due to a significant decline in its U.S. companion animal business, attributed to increased price sensitivity, fewer vet visits, and generic competition. The company is implementing a broad reset focusing on integrated solutions, cost controls, and operational efficiency, following a substantial drop in its share price. This strategic shift aims to address the challenges in its pet segment while leveraging its more resilient livestock and international businesses.
CDW Corp (CDW) Stock Price, Quote, News & History
This article provides a comprehensive overview of CDW Corp (CDW) stock, including its current price, recent news, key financial statistics, and analyst trends. It highlights the stock's performance, dividend information, and upcoming events like earnings releases and conference calls. The company operates in the Information Technology sector, providing IT solutions to various clients.
ETFs Investing in Zoetis, Inc. Class A Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Zoetis, Inc. Class A stocks. It provides a detailed table including fund symbol, market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return for each ETF. The information aims to help investors find accessible and lower-risk opportunities to invest in Zoetis through these funds.
Here’s Why IDEXX Laboratories Stock Could Deliver Around 11% Annual Returns Despite a 15% YTD Pullback
IDEXX Laboratories (IDXX) delivered strong Q1 2026 results with revenue up 14% and diluted EPS up 17%, and subsequently raised its full-year guidance. Despite a 15% year-to-date pullback, analysts project the stock could rise to around $763 per share by December 2028, representing an annualized return of approximately 11%. This positive outlook is driven by the company's expanding base of diagnostic instruments, recurring consumable revenues from companion animal testing, and sustained pricing power within the veterinary diagnostics market.
Zoetis Earnings: Heightened Competition Leads to Weak Quarter, Putting Zoetis Under Review
Zoetis reported first-quarter revenue of $2.26 billion and adjusted net income of $646 million, leading to flat organic operational growth and a 1% year-over-year increase, respectively. The company also lowered its 2026 guidance for revenue and earnings, attributing the weak quarter to heightened competition. Morningstar has placed Zoetis under review due to these results.
20/20 Biolabs Unchanged on News
20/20 BioLabs, Inc. (NASDAQ: AIDX) shares saw a slight decrease despite announcing that Maryland fire departments will receive over $520,000 to use the company's OneTest™ multi-cancer early detection blood test. This funding, from the state's cancer screening grant program, will enable over 1,400 firefighters to be tested, representing a significant increase from last year. A representative from the Salisbury Fire Department expressed satisfaction with the OneTest screenings and their ability to facilitate timely follow-up care for their members.
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Zoetis Inc.
Ademi LLP has launched an investigation into potential securities fraud claims against Zoetis (NYSE: ZTS). The investigation stems from concerns that Zoetis may have made inaccurate statements regarding its financial performance, business operations, and future prospects. This alert follows Zoetis' acknowledgment that customers are reducing spending on non-emergency pet healthcare treatments.
U.S. Indexes Closed Down Thursday; Insmed Fell Furthest
On Thursday, U.S. stock indexes experienced declines across the board. The Dow Jones Industrial Average fell by 0.63%, the S&P 500 Index decreased by 0.38%, and the NASDAQ Composite Index saw a 0.13% drop. Insmed was noted as the stock that fell the furthest.
Qualcomm, Datadog among market cap stock movers on Thursday
On Thursday, major stock market movers included Qualcomm and Datadog, which saw rallies, while Arm and Insmed experienced declines. The article categorizes these movers by market capitalization (mega-cap, large-cap, mid-cap, and small-cap) and provides specific percentage changes and reasons for their movements, such as earnings reports, guidance changes, or analyst upgrades. It highlights that the stock performance was driven by various news and company-specific factors.
ZOETIS ($ZTS) Releases Q1 2026 Earnings
Zoetis ($ZTS) released its Q1 2026 earnings, reporting $1.53 per share, which missed analyst estimates of $1.63. The company also fell short on revenue, posting $2.262 billion against an estimated $2.328 billion. The article further details insider trading, hedge fund activity, government contracts, congressional stock trading, analyst ratings, and price targets related to ZTS.
Elanco Is Finally Realizing Its Transformation From Caterpillar to Butterfly
Elanco, a major animal drug producer, has faced challenges in becoming a more dominant and profitable competitor despite a sound strategy focused on innovation. The firm is now beginning to realize its potential, a transformation highlighted by strong product performance. This shift is expected to improve its competitive standing and profitability in the long run.
Global Animal Euthanasia Market to Reach $3.26 Billion by 2036,
The global animal euthanasia market is projected to reach $3.26 billion by 2036, growing at a CAGR of 6.5% from an estimated $1.74 billion in 2026, according to Fact.MR. This growth is driven by expanding veterinary infrastructure, stricter regulatory standards, and the "humanization" of companion animals. Euthanasia drugs and companion animals are expected to dominate market shares, with promising growth in emerging markets like South Africa and China.
Earnings call transcript: Tigo Energy Q1 2026 sees 33.7% revenue growth
Tigo Energy reported a strong Q1 2026 with a 33.7% year-over-year revenue increase to $25.2 million and an improved gross margin of 42.8%. Despite seasonal sequential declines, the company saw a 74.3% reduction in net loss and a 10.73% stock price surge post-earnings. Strategic initiatives include expanding the GO ESS battery platform and leveraging partnerships for growth in the US and European markets, with analysts forecasting 29% revenue growth for fiscal 2026.
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Analysts are forecasting a year-over-year decline in earnings and revenues for Heron Therapeutics (HRTX) for the quarter ended March 2026. The company is expected to report a quarterly loss of $0.03 per share, a 400% decrease from the prior year, with revenues down 7.1% to $36.13 million. The Zacks Earnings ESP indicates a potential earnings miss for HRTX, while an industry peer, Zoetis (ZTS), is expected to beat earnings estimates.
52-Week Low Stocks: IBM, CoStar Group, and Zoetis in Focus - News and Statistics
This article analyzes three stocks that have recently hit 52-week lows: IBM, CoStar Group, and Zoetis. It suggests "selling" IBM and CoStar due to reasons like slow revenue growth, declining profitability, and eroding returns on capital, while Zoetis is presented as a stock "to watch" without further detailed analysis. The analysis emphasizes the importance of fundamental company analysis beyond just stock price charts to assess potential recovery or long-term decline.
10 Exceptional Stocks With Double-Digit Dividend Raises
This article identifies a rare group of 10 dividend-paying stocks that have consistently achieved double-digit dividend growth for five consecutive years and passed rigorous checks. David Harrell of Morningstar DividendInvestor newsletter discusses the qualifications for this list, including three newcomers for 2026, and highlights five of these stocks that Morningstar analysts consider undervalued. The piece also looks ahead to potential dividend growers for 2027, noting some candidates poised to maintain their status and one likely to slip.
Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay
Praxis Precision Medicines, Inc. is holding its 2026 virtual annual meeting on June 10, 2026, where stockholders will vote on the election of three Class III directors, the ratification of Ernst & Young LLP as auditor, and an advisory Say-on-Pay resolution regarding executive compensation. The company reported a 283% one-year return for stockholders in 2025, driven by significant clinical, regulatory, and capital-raising milestones. Praxis has also evolved its executive compensation program for 2026 to include performance-based restricted stock units (PSUs) to further align executive incentives with company performance and long-term value creation.
Though Zoetis' Wide Moat Remains Strong, We've Trimmed Long-Term Assumptions and Valuation
Morningstar has reaffirmed Zoetis' wide economic moat, recognizing its leadership and innovative product portfolio in the global animal health industry. However, the firm has trimmed its long-term assumptions and valuation for Zoetis. This adjustment comes despite Zoetis' strong market position, which includes expansion into various animal health markets like aquaculture and pet diagnostics.
Vanguard holds 30.277M Zoetis shares (NYSE: ZTS) — 7.17% stake
Vanguard Capital Management reported beneficial ownership of 30,277,753 shares of Zoetis Inc. (NYSE: ZTS), representing a 7.17% stake as of March 31, 2026. The Schedule 13G filing indicates Vanguard has sole dispositive power over all 30.277 million shares and sole voting power over 4,204,907 shares. This disclosure classifies Vanguard as a passive investor in Zoetis Inc.
National Fuel Gas (NYSE:NFG) Issues Quarterly Earnings Results
National Fuel Gas (NYSE:NFG) announced its quarterly earnings, reporting an EPS of $2.71, missing the consensus estimate of $2.85 by $0.14, although revenue of $858.37 million exceeded estimates. The company provided fiscal 2026 guidance of $7.45–$7.75 EPS and declared a quarterly dividend of $0.535. Analysts maintain a "Moderate Buy" rating with a $106 target price.
Elanco Animal Health (ELAN) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Michael Ryskin has maintained a Buy rating for Elanco Animal Health (ELAN) with a price target of $30.00. Ryskin, a 3-star analyst, has an average return of 1.0% and a 47.38% success rate, focusing on the Healthcare sector. The analyst consensus for Elanco Animal Health is currently a Strong Buy with an average price target of $29.40.
